Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225172 · ClinicalTrials.gov registry record · Phase 2
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT01225172 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 77 participants.
The verdict
NCT01225172, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.
Interventions
- DRUG letrozole
- DRUG BMS-754807
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2010-12-31 |
| Est. Completion | 2014-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01225172
The ClinicalTrials.gov registry entry for NCT01225172 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which letrozole is the first listed.
NCT01225172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01225172 about?
NCT01225172 is a clinical study titled "Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors". The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.
What is the current status of trial NCT01225172?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2010-12-31. Estimated completion is 2014-11-30.
What interventions are being tested in trial NCT01225172?
The interventions under investigation include: letrozole (DRUG), BMS-754807 (DRUG).
Who is sponsoring clinical trial NCT01225172?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.